Respire_final-01
  • CORPORATE
    • Company Overview
    • Company Management
    • Board of Directors
    • Patents
    • Financial Summary
    • Social Media Guidelines
  • BREATHING DISORDERS
    • Brain-controlled Breathing Disorders
    • Respiratory Depression
    • Sleep Apnea
    • Other Breathing Disorders
    • Additional Reading
  • DEVELOPMENT PROGRAMS
    • Ampakines Platform – As of July 2017
    • Cannabinoids Platform – As of August 2018
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
    • Financial Summary
  • CONTACT

RespireRx Announces Debt Forgiveness for Past Due Cash Compensation

December 15, 2017j3ff1
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.